Recent Updates — ENTA
The Unified Patent Court (UPC) has ruled European Patent No. EP 4 051 265 invalid and dismissed Enanta Pharmaceuticals' infringement lawsuit against Pfizer Inc. regarding the sale of Paxlovid in 18 EU member states. The decision concludes a hearing held on September 29, 2026, where Pfizer counterclaimed for revocation of the patent. This ruling eliminates Enanta's intellectual property rights to nirmatrelvir in the affected jurisdictions and removes potential litigation damages or licensing revenue from this specific legal action. Enanta Pharmaceuticals operates as a biopharmaceutical company focused on developing treatments for infectious diseases.
Enanta Pharmaceuticals announced that President and CEO Jay R. Luly will retire by February 1, 2027, following 23 years of leadership. Dr. Luly will serve as a strategic advisor through the end of 2027 to support the transition. The Board has initiated a search for his successor. Concurrently, the company appointed Tara L. Kieffer, previously Chief Product Strategy Officer, to the newly created role of Chief Operating Officer. Enanta is a clinical-stage biotechnology company developing small molecule drugs for viral infections and immunological diseases.
Enanta Pharmaceuticals reported fiscal third quarter results ending June 30, 2026. Revenue was $14.4 million, down from $18.3 million in the prior year period due to lower AbbVie HCV sales. The company incurred a net loss of $19.5 million, or $0.67 per diluted share, compared to a $18.3 million loss previously. R&D expenses decreased to $22.1 million from $27.2 million as RSV trial costs declined. Cash and marketable securities totaled $211.5 million, providing a runway into fiscal 2029. Clinically, dosing began in the Phase 2b LOTUS pediatric RSV trial with topline data expected in 2027. The registrational RESOLVE adult RSV trial is on track for Q4 2026 initiation. Topline data from the Phase 1 EDP-978 urticaria trial and an IND filing for EPS-3903 are also targeted for late 2026. Enanta Pharmaceuticals, Inc. operates in the biotechnology industry, developing small molecule drugs for viral infections and immunological diseases.
Enanta Pharmaceuticals, Inc. entered into an Open Market Sale Agreement with Jefferies LLC to sell up to $75,000,000 in common stock through an at-the-market offering. The company will pay Jefferies LLC a commission of up to 3.0% of the gross sales price per share. Enanta Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing small molecule drugs.
The Federal Circuit affirmed a summary judgment decision ruling that the claims of U.S. Patent No. 11,358,953 are invalid, impacting Enanta Pharmaceuticals' lawsuit against Pfizer Inc. regarding Paxlovid infringement. Enanta Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing small molecule drugs.
Enanta Pharmaceuticals, Inc. announced the advancement of its zelicapavir clinical development program for the treatment of respiratory syncytial virus (RSV), including plans for a registrational Phase 2b/3 clinical trial in high-risk adults and a Phase 2b clinical trial in pediatric patients. Enanta Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing small molecule drugs for infectious diseases.